Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anthony Jospeh, MD
Ophthalmic Consultants of Boston
Principal Investigator - David Liao, MD
Retina-Vitreous Associates Medical Group, Los Angeles CA
Principal Investigator - Mitul Mehta, MD
University of California, Irvine/Gavin Herbert Eye Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gavin Herbert Eye Inst, Univ Cal Irvine
Irvine, California, United States
- Retina-Vitreous Associates Medical Group
Los Angeles, California, United States
- Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Dec 2020
- Primary completion
- 22 Mar 2022
- Completion
- 22 Mar 2022
- Last update posted
- 16 Jul 2024
- Registered enrollment
- 30
- Registry id
- NCT04604899
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.